Keros Therapeutics (KROS) Change in Receivables (2021 - 2025)
Keros Therapeutics (KROS) posted Change in Receivables of $75000.0 for Q4 2025, up 100.61% on a QoQ basis from -$12.3 million in Q3 2025, and down 96.81% year-over-year from $2.4 million in Q4 2024.
Keros Therapeutics (KROS) Change in Receivables (2021 - 2025) Analysis & Trends
Keros Therapeutics' Change in Receivables history runs 5 years deep, the most recent figure standing at $75000.0 for Q4 2025.
- Quarterly Change in Receivables fell 96.81% year-over-year to $75000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $825000.0 (down 68.26% YoY) and the FY2025 annual result came in at $825000.0, down 68.26% from the prior year.
- Change in Receivables was $75000.0 for Q4 2025 at Keros Therapeutics, up from -$12.3 million in the prior quarter.
- Across five years, Change in Receivables topped out at $18.0 million in Q4 2021 and bottomed at -$18.0 million in Q1 2022.
- A 5-year average of $274384.6 and a median of $83000.0 in 2024 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 17428.92% in 2025, while the deepest fall reached 3309.38% in 2025.
- Keros Therapeutics' Change in Receivables stood at $18.0 million in 2021, then plunged by 200.0% to -$18.0 million in 2022, then surged by 100.79% to $143000.0 in 2023, then surged by 1546.15% to $2.4 million in 2024, then plunged by 96.81% to $75000.0 in 2025.
- Business Quant data shows KROS's Change in Receivables at $75000.0 in Q4 2025, -$12.3 million in Q3 2025, and -$1.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | 75,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 75,000.00 |
| Dec 31, 2025 | 75,000.00 |
| Sep 30, 2025 | -12.32 Mn |
| Sep 30, 2025 | -12.32 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 384,000.00 |
| Sep 30, 2024 | 384,000.00 |
| Jun 30, 2024 | -222,000.00 |
| Jun 30, 2024 | -222,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Mar 31, 2022 | -18.00 Mn |
| Mar 31, 2022 | -18.00 Mn |